OWKIN in the news
AI biology discovery platform
Tamtam found 20 recent articles about OWKIN.
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin and Sanofi are expanding their collaboration to develop AI-driven biopharma agents and integrate Owkin's K Pro platform into Sanofi's drug discovery and development processes.
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin partners with Sanofi for a multi-year collaboration to develop AI agents for drug discovery and development, leveraging Owkin's K Pro AI platform.
- Owkin: Pioneering Biological Artificial Superintelligence for the Future of Medicine
Owkin is pioneering Biological Artificial Superintelligence to accelerate drug discovery, diagnostics, and clinical decisions through an autonomous AI Scientist and a closed-loop system.
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin partnered with Sanofi for a multi-year collaboration to co-develop next-generation biopharma AI agents using Owkin's K Pro AI Scientist platform.
- Q&A: Owkin’s five-year Sanofi deal bets on ‘purpose-built’ AI agents
Owkin has partnered with Sanofi and AstraZeneca to deploy specialized AI agents for drug discovery and competitive intelligence through its K Pro platform.
- Sanofi expands AI ambitions through new Owkin collaboration
Sanofi is expanding its partnership with Owkin to develop AI agents for pharmaceutical research and development.
- Owkin and Sanofi Expand Partnership to Develop AI Agents Through K Pro Collaboration
Sanofi is expanding its partnership with Owkin to integrate autonomous AI agents and the K Pro platform into its pharmaceutical R&D workflows for faster drug discovery.
- Sanofi and Owkin partner to develop next-generation biopharma AI agents
Sanofi and Owkin are partnering to build autonomous AI agents and use the K Pro platform to accelerate drug discovery and development decision-making.
- Sanofi Owkin AI Deal Puts R&D Shift And Valuation In Focus
Sanofi and Owkin are collaborating on a multi-year project to integrate agentic AI systems into drug research and development to improve R&D productivity.
- Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi
Owkin is collaborating with Sanofi on a multi-year project to build AI agents for drug discovery and personalized medicine.
- Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative - Sanofi (NASDAQ:SNY)
Sanofi is expanding its collaboration with Owkin to deploy custom AI agents and the K Pro platform for faster drug discovery and clinical development decisions.
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin and Sanofi are collaborating on a multi-year project to integrate AI agents and the K Pro platform into Sanofi's drug development processes.
- Sanofi deepens its Owkin bet with a five-year deal to build bespoke drug-development agents
Sanofi is integrating Owkin's K Pro AI platform into its own research stack to accelerate drug development through autonomous agentic systems.
- Owkin, Sanofi expand AI collaboration to build drug development AI agents
Owkin and Sanofi are co-developing autonomous AI agents through the K Pro platform to automate and accelerate drug discovery and clinical development tasks.
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin and Sanofi are collaborating to integrate autonomous AI agents into the drug development process using the K Pro platform.
- Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
Sanofi and Owkin are deepening their partnership to develop agentic AI and utilize the K Pro platform for faster pharmaceutical R&D and decision-making.
- Why AI models need patient data to deliver in drug discovery
Owkin is leveraging real-world patient data and agentic AI to bridge the gap between computational drug discovery and successful clinical outcomes in oncology.
- OWKIN Showcases AI-Driven Trial De-Risking Capabilities at Harvard Symposium
AI-driven trial de-risking capabilities and the K Pro research tool were showcased at a Harvard University symposium.
- OWKIN Highlights AI Metric Choice to Improve Oncology Target Discovery
Precision metrics for AI-driven oncology target discovery are being prioritized to improve drug development efficiency and partner value.
- OWKIN Deepens U.K. Data Network and Sharpens AI Biology Strategy Amid Sector Funding Shifts
Expanded its U.K. clinical data network and validated its AI platform by identifying novel bladder cancer targets.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like OWKIN?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies